Functional heterogeneity and clinical implications of CD4+ T cell subtypes in high-grade serous ovarian carcinoma

doi:10.5306/wjco.v16.i5.104138

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

HTML

Figures (1-5)

Sum=16

May 24, 2025 (publication date) through May 19, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Clin Oncol. May 24, 2025; 16(5): 104138
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.104138

Full Size Figure Download Figure

Figure 4 Tissue-specific adaptations and functional heterogeneity of CD4+ Treg subtypes in high-grade serous ovarian carcinoma. A: Functional Diversity of CD4+ Treg subtypes in high-grade serous ovarian carcinoma (HGSOC); B: Hierarchical clustering of CD4+ Treg subtypes across adnexal and ascitic microenvironments in HGSOC; C: Comparative functional profiling of CD4+ Treg subtypes between adnexa and ascites in HGSOC; D: Differential pathway enrichment of CD4+ Treg subtypes between adnexa and ascites in HGSOC.

Citation: Zhang BL, Gao W, He L, Liu XT, Wang ZM, Tan L. Functional heterogeneity and clinical implications of CD4+ T cell subtypes in high-grade serous ovarian carcinoma. World J Clin Oncol 2025; 16(5): 104138
URL: https://www.wjgnet.com/2218-4333/full/v16/i5/104138.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i5.104138